Description
PT-141 Bremelanotide is a peptide that’s developed by Palatin Technologies used mainly as a treatment for male ED (erectile dysfunction), FSD (female sexual dysfunction), reperfusion injury and hemorrhagic shock.
It has also shown potential effects in improving social cognition as well as behaviour, which is also what promotes the peptide as a treatment for a disorder called autism.
Specification
CAS register number | 32780-32-8 |
Molecular formula | C50H68N14O10 |
Molecular weight | 1025.2 |
Purity(HPLC) | 98.80% |
Water | 5.40% |
Appearance | White to off white powder |
Peptide | 84.20% |
Acetic Acid | 5.35% |
Trifluoroacetic Acid | 0.11% |
Single Impurity(HPLC) | 1.0%max |
Amino Acid Composition | ±10% of theoretical |
Peptide Content(N%) | ≥80.0% |
Water Content(Karl Fischer) | ≤6.0% |
Acetate Content(HPIC) | ≤15.0% |
Mass Balance | 95.0~105.0% |
Grade | Pharmaceutical Grade |
MS(ESI) | Consistent |
Benefits
- Increased sexual drive
- Improvement of sexual potency
- Increased sensibility
- Increased coitus duration
Dosage
To achieve first results it is enough to administrate 0.3 milligrams of the preparation subcutaneously. It is the initial dose allowing to define the effect of the active components on the organism. Further the dosage can be increased if necessary. The optimal dosage for one administration is between 0.5 and 1.5 milligrams.
The first signs of the effectiveness of Bremelanotide appear in a couple of hours after administration. The maximum effect is reached after 3-4 hours. Totally the active substance's effect lasts for 8-10 hours.
